CRISPR

CRISPR2-shank3b

ID

ZDB-CRISPR-190807-2

Name

CRISPR2-shank3b

Previous Names

None

Target

shank3b (1)

Sequence

5' - GGTGTCCTGAAGAATGATCATGG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
umi102	shank3b

Expression

Gene expression in Wild Types + CRISPR2-shank3b

No data available

Phenotype

Phenotype resulting from CRISPR2-shank3b

No data available

Phenotype of all Fish created by or utilizing CRISPR2-shank3b

Phenotype	Fish	Conditions	Figures
intestinal motility disrupted, abnormal	AB + CRISPR11-shank3a + CRISPR2-shank3b	standard conditions	Fig. 3 from James et al., 2019
intestine peristalsis decreased frequency, abnormal	AB + CRISPR11-shank3a + CRISPR2-shank3b	standard conditions	Fig. 3 from James et al., 2019
intestinal motility decreased rate, abnormal	shank3a^umi101/+; shank3b^umi102/+ (AB)	standard conditions	Fig. 4 from James et al., 2019
intestine peristalsis decreased frequency, abnormal	shank3a^umi101/+; shank3b^umi102/+ (AB)	standard conditions	Fig. 3 from James et al., 2019
intestine has fewer parts of type enteroendocrine cell, abnormal	shank3a^umi101/+; shank3b^umi102/+ (AB)	standard conditions	Fig. 7 from James et al., 2019
intestinal bulb intestine smooth muscle contraction disrupted, abnormal	shank3a^umi101/+; shank3b^umi102/+ (AB)	standard conditions	Fig. 4 from James et al., 2019
intestinal motility disrupted, abnormal	shank3a^umi101/+; shank3b^umi102/+ (AB)	standard conditions	Fig. 3 from James et al., 2019
intestine has extra parts of type goblet cell, abnormal	shank3a^umi101/+; shank3b^umi102/+ (AB)	standard conditions	Fig. S2 from James et al., 2019
intestine peristalsis decreased frequency, abnormal	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB)	standard conditions	Fig. 3 from James et al., 2019
intestine has fewer parts of type enteroendocrine cell, abnormal	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB)	standard conditions	Fig. 7 from James et al., 2019
intestine has extra parts of type goblet cell, abnormal	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB)	standard conditions	Fig. S2 from James et al., 2019
intestine lumen decreased diameter, abnormal	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB)	standard conditions	Fig. S2 from James et al., 2019
intestinal motility disrupted, abnormal	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB)	standard conditions	Fig. 3 from James et al., 2019
intestinal villus swollen, abnormal	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB)	standard conditions	Fig. S2 from James et al., 2019
swimming behavior process quality, ameliorated	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB/TL)	chemical treatment by environment: risperidone	Fig. 3 from Kozol et al., 2023
swimming behavior decreased process quality, abnormal	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB/TL)	lighting conditions	Fig. 1 , Fig. 3 , Fig. 4 , Fig. 5 , Fig. 6 from Kozol et al., 2023
visual behavior decreased process quality, abnormal	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB/TL)	chemical treatment by environment: lithium chloride	Fig. 4 from Kozol et al., 2023
visual behavior decreased process quality, abnormal	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB/TL)	lighting conditions	Fig. 1 , Fig. 3 , Fig. 4 , Fig. 5 , Fig. 6 from Kozol et al., 2023
swimming behavior decreased process quality, abnormal	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB/TL)	chemical treatment by environment: lithium chloride	Fig. 4 from Kozol et al., 2023
visual behavior process quality, exacerbated	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB/TL)	chemical treatment by environment: risperidone	Fig. 3 from Kozol et al., 2023
visual behavior decreased process quality, abnormal	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB/TL)	chemical treatment by environment: carbamazepine	Fig. 5 from Kozol et al., 2023
visual behavior process quality, exacerbated	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB/TL)	chemical treatment by environment: 2-methyl-6-(phenylethynyl)pyridine	Fig. 6 from Kozol et al., 2023
swimming behavior process quality, exacerbated	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB/TL)	chemical treatment by environment: 2-methyl-6-(phenylethynyl)pyridine	Fig. 6 from Kozol et al., 2023
swimming behavior decreased process quality, abnormal	shank3a^{umi101/umi101}; shank3b^{umi102/umi102} (AB/TL)	chemical treatment by environment: carbamazepine	Fig. 5 from Kozol et al., 2023

Citations